KRAS and neoplasm: Mutations in SMAD4 were significantly more common in LS-EC (8% vs. 0%, p = 0.04), whereas mutations in PDGFRB (0% vs. 10%, p = 0.01), ALK (0% vs. 8%, p = 0.02), IDH1 (0% vs. 2%, p = 0.03), CARD11 (0% vs. 8%, p = 0.02) and KRAS (20% vs. 39%, p = 0.02) were significantly more common in sporadic MMRd tumours (Figure 2).